Oncopeptides AB

ProteoValent Therapeutics

This company develops targeted protein degrader therapies for cancer and haematology patients.

APIM Therapeutics AS

This clinical-stage biotechnology company develops peptide drugs targeting cellular stress responses to treat patients with advanced solid tumours and multiple cancers.

Ascelia Pharma

This biotech company develops orphan oncology drugs, including contrast agents for liver imaging and oral treatments for patients with rare cancer conditions.

Aprea Therapeutics

This company develops targeted cancer therapies for patients with biomarker-defined tumours and DNA damage response pathway defects.

Apim Therapeutics

This clinical-stage biotechnology company develops peptide drugs targeting cellular stress responses for patients with advanced cancers including ovarian cancer and sarcoma.

CARGO Therapeutics

This biotechnology company develops engineered cell therapies to treat cancer patients with relapsed or resistant lymphoma.

Nurix Therapeutics

This company develops targeted protein degradation therapies to treat patients with cancer and autoimmune diseases.

Proteolix

This biopharmaceutical company develops proteasome-inhibitor drugs for patients with multiple myeloma and other cancer types.